Feb

2012

CeNeRx BioPharma, Inc.: Series D $4.6M

Posted in I - Series C, Q - 4Q11, R - SOUTH EAST, X - Anxiety, X - CNS, X - Depression, XX - NC

CeNeRx (Cary, NC) a clinical-stage biopharmaceutical company focused on diseases of the central nervous system, depression and anxiety, closed a $4.6M Series D financing. Participants include Aisling Capital, L Capital Partners, Perseus Soros Biopharmaceutical Fund, Omega Funds and Pappas Ventures.

Jan

2012

PharmacoFore, Inc.: Series A $10M

Posted in I - Series A, Q - 4Q11, R - WEST, X - Addiction, X - CNS, X - Neurology, X - Pain, XX - CA

PharmacoFore (San Carlos, CA) a clinical-stage biopharmaceutical company focused on improvement of existing drugs preventing misuse, abuse, and overdose of prescription medications for pain, closed a $10M Series A financing. Participants include Founders Fund.

Oct

2011

MSI Methylation Sciences, Inc.: Series A $18.2M

Posted in I - Series A, Q - 3Q11, R - INTERNATIONAL, X - CNS, X - Depression

MSI Methylation Sciences (Canada) a preclinical-stage pharmaceutical company focused on depression, closed a $18.2M Series A financing. Participants include Inventages, GrowthWorks and BC Advantage Funds.

Jul

2011

Prexa Pharmaceuticals, Inc.: Series B $7M

Posted in I - Series B, Q - 2Q11, R - NORTH EAST, X - CNS, XX - MA

Prexa Pharmaceuticals (Boston, MA) a preclinical-stage biotechnology company focused on ADHD, depression, Parkinson’s and other CNS related diseases, closed a $7.0M Series B financing. Participants include Advent Healthcare Ventures and Shire.

Jul

2011

Naurex, Inc.: Series A $18M

Posted in I - Series A, Q - 2Q11, R - MID WEST, X - CNS, X - Depression, XX - IL

Naurex (Evanston, IL) a clinical-stage pharmaceutical company focused on depression and other CNS-related disorders, closed a $18M Series A financing. Participants include Adams Street Partners, Latterell Venture Partners, Druid BioVentures, Genesys Capital, PathoCapital, Lundbeck, Takeda Ventures and Shire.

Jul

2011

Delenex Therapeutics, AG: Series A $19.3M

Posted in I - Series A, Q - 2Q11, R - INTERNATIONAL, X - CNS, X - Dermatology

Delenex (Switzerland) a preclinical-stage biopharmaceutical company focused on CNS and dermatological diseases closed a $19.3M Series A financing, bringing the total round to $38.4M. Participants include Novo Ventures, SV Life Sciences, HBM BioCapital, HBM BioVentures, BioMedInvest and VI Partners.

May

2011

Mithridion, Inc.: Series C $1.2M

Posted in I - Series C, Q - 1Q11, R - MID WEST, X - Alzheimer's, X - CNS, X - Schizophrenia, XX - WI

Mithridion (Madison, WI) a clinical-stage biopharmaceutical company focused on CNS disorders with an initial focus on Alzheimer’s and schizophrenia, closed a $1.2M Series C financing. Participants include, Venture Investors, the State of Wisconsin Investment Board and Rocket Venture Fund.

Apr

2011

NextWave Pharmaceuticals, Inc.: Series C $45M

Posted in I - Series C, Q - 1Q11, R - WEST, X - CNS, X - Cardiology, XX - CA

NextWave Pharmaceuticals (Cupertino, CA) a clinical-stage specialty pharmaceutical focused on cardiovascular and CNS diseases, closed a $45M Series C financing. Participants include Panorama Capital, Bay City Capital, Kearny Venture Partners, Aisling Capital, Fidelity Biosciences, Sofinnova Ventures and Vivo Ventures.

Jan

2011

Acylin Therapeutics, Inc.: Series A $4.4M

Posted in I - Series A, Q - 4Q10, R - NORTH WEST, X - CNS, X - Metabolism, X - Oncology, XX - WA

Acylin Therapeutics (Seattle, WA) a development-stage biopharma company focused on inhibiting histone acetyltransferase in cancer, metabolic disease, and neurodegeneration indications, closed a $4.4M Series F financing. Participants include Alexandria Real Estate Equities, Amgen Ventures, ARCH Venture Partners, OVP Venture Partners, PPD and Washington Research Foundation Capital.

Jan

2011

Mind-NRG, SA: Series A $2M

Posted in I - Series A, Q - 4Q10, R - INTERNATIONAL, X - Alzheimer's, X - CNS, X - Parkinson's, X - Schizophrenia

Mind-NRD (Switzerland) a development-stage biopharmaceutical company focused on a neurotrophic factor for the treatment of Parkinson’s, Alzheimer’s and schizophrenia, closed a $2M Series A financing. Participants include Index Ventures.

Nov

2010

Delenex Therapeutics, AG: Series A $14M

Posted in I - Series A, Q - 4Q10, R - INTERNATIONAL, X - Antibody, X - CNS, X - Dermatology

Delenex Therapeutics (Switzerland) a clinical-stage biopharmacetucial company developing therapeutic antibody fragments targeting CNS and dermatological disease, closed a $14M Series A financing. Participants include SV Life Sciences, HBM BioCapital, BioMed Partners and VI Partners.

Oct

2010

Euthymics Bioscience, Inc.: Seris A $24M

Posted in I - Series A, Q - 3Q10, R - NORTH EAST, X - CNS, X - Depression, XX - MA

Euthymics Bioscience (Cambridge, MA) a clinical-stage small molecule company focused on CNS disorders and depression, closed a $24M Series A financing. Participants include Novartis Venture Fund, Venture Investors, H&Q Capital Management and GBS Venture Partners.

Aug

2010

CeNeRx BioPharma, Inc.: Series C $10M

Posted in I - Series C, Q - 3Q10, R - SOUTH EAST, X - CNS, XX - NC

CeNeRx (Cary, NC) a clinical-stage biopharmaceutical company focused on diseases of the central nervous system, closed a $10M Series C, bringing the round total to $14M. Participants include Aisling Capital, L Capital Partners and Pappas Ventures.

« Previous Entries

to top of page...